CA2902656A1 - Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor - Google Patents

Info

Publication number

CA2902656A1

CA2902656A1 CA2902656A CA2902656A CA2902656A1 CA 2902656 A1 CA2902656 A1 CA 2902656A1 CA 2902656 A CA2902656 A CA 2902656A CA 2902656 A CA2902656 A CA 2902656A CA 2902656 A1 CA2902656 A1 CA 2902656A1

Authority

CA

Canada

Prior art keywords

trans

ethyl

hydroxy

tert

piperazin

Prior art date

2013-03-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 325
• 108090000525 Dopamine D3 Receptors Proteins 0.000 title claims abstract description 31
• 102000004073 Dopamine D3 Receptors Human genes 0.000 title claims abstract description 31
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 391
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 76
• 150000003839 salts Chemical class 0.000 claims abstract description 49
• 150000001204 N-oxides Chemical class 0.000 claims abstract description 45
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
• 239000001257 hydrogen Substances 0.000 claims abstract description 34
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 24
• 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 17
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims abstract description 17
• 125000005475 oxolanyl group Chemical group 0.000 claims abstract description 17
• 125000003566 oxetanyl group Chemical group 0.000 claims abstract description 15
• 229910052731 fluorine Inorganic materials 0.000 claims abstract description 13
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 11
• 239000011737 fluorine Substances 0.000 claims abstract description 11
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 9
• 239000001301 oxygen Substances 0.000 claims abstract description 9
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 7
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 5
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 3
• -1 cyclic radical Chemical class 0.000 claims description 414
• 150000003254 radicals Chemical class 0.000 claims description 156
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 85
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 73
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 72
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 58
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 56
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims description 54
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 54
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 52
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 52
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 51
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 51
• 208000035475 disorder Diseases 0.000 claims description 50
• 238000000034 method Methods 0.000 claims description 47
• 239000000651 prodrug Substances 0.000 claims description 44
• 229940002612 prodrug Drugs 0.000 claims description 44
• 239000003814 drug Substances 0.000 claims description 33
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 33
• 238000011282 treatment Methods 0.000 claims description 33
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 26
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
• 239000000126 substance Substances 0.000 claims description 22
• 208000011117 substance-related disease Diseases 0.000 claims description 16
• 125000000217 alkyl group Chemical group 0.000 claims description 15
• 208000019901 Anxiety disease Diseases 0.000 claims description 14
• 201000000980 schizophrenia Diseases 0.000 claims description 14
• 208000012661 Dyskinesia Diseases 0.000 claims description 13
• 208000018737 Parkinson disease Diseases 0.000 claims description 13
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 230000036506 anxiety Effects 0.000 claims description 11
• 208000010877 cognitive disease Diseases 0.000 claims description 11
• 239000003446 ligand Substances 0.000 claims description 8
• 206010062237 Renal impairment Diseases 0.000 claims description 7
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 6
• 208000020925 Bipolar disease Diseases 0.000 claims description 6
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 6
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 6
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 6
• 208000030814 Eating disease Diseases 0.000 claims description 5
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
• 208000002193 Pain Diseases 0.000 claims description 5
• 210000003169 central nervous system Anatomy 0.000 claims description 5
• 235000014632 disordered eating Nutrition 0.000 claims description 5
• 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
• NXWBOAQGGZVKBT-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1C[CH]C1 NXWBOAQGGZVKBT-UHFFFAOYSA-N 0.000 claims description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
• 230000008450 motivation Effects 0.000 claims description 4
• 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 claims description 3
• 206010013654 Drug abuse Diseases 0.000 claims description 3
• XIPDODHKFSTWGQ-UNCSOSLYSA-N CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 XIPDODHKFSTWGQ-UNCSOSLYSA-N 0.000 claims description 2
• XIPDODHKFSTWGQ-YROJFRDXSA-N CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 XIPDODHKFSTWGQ-YROJFRDXSA-N 0.000 claims description 2
• UDRZDLDHIYMICU-CXTGUETESA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-CXTGUETESA-N 0.000 claims description 2
• ZKQGJMPEAJQJIT-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(CC1)CCC1NC(=O)C1CCC(O)CC1 ZKQGJMPEAJQJIT-UHFFFAOYSA-N 0.000 claims 2
• UMVJFUPSFWNGLR-BIQTVELOSA-N C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2CCN(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 Chemical compound C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2CCN(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 UMVJFUPSFWNGLR-BIQTVELOSA-N 0.000 claims 1
• MFDCOFBYJDNAHX-CRIZEEMZSA-N C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2C[C@H](C)N(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 Chemical compound C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2C[C@H](C)N(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 MFDCOFBYJDNAHX-CRIZEEMZSA-N 0.000 claims 1
• JNJLNDBHIQMMPS-NMICXILDSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 JNJLNDBHIQMMPS-NMICXILDSA-N 0.000 claims 1
• HFUDTZKQQFGRIB-UNCSOSLYSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 HFUDTZKQQFGRIB-UNCSOSLYSA-N 0.000 claims 1
• HFUDTZKQQFGRIB-YROJFRDXSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 HFUDTZKQQFGRIB-YROJFRDXSA-N 0.000 claims 1
• WPXYHLDUFCEGNH-KHDOTFDESA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CC(C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CC(C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 WPXYHLDUFCEGNH-KHDOTFDESA-N 0.000 claims 1
• GIAFISQEJLFPRO-ONXIHUBWSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 GIAFISQEJLFPRO-ONXIHUBWSA-N 0.000 claims 1
• XNYXVAQMIGIMNF-KHDOTFDESA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)C)=N1 XNYXVAQMIGIMNF-KHDOTFDESA-N 0.000 claims 1
• RWBKBXNQRHXCFO-CASZSKKGSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3C[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3C[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 RWBKBXNQRHXCFO-CASZSKKGSA-N 0.000 claims 1
• PWTMJTJEUYXRGM-STUVXCIXSA-N CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 PWTMJTJEUYXRGM-STUVXCIXSA-N 0.000 claims 1
• PWTMJTJEUYXRGM-CHDDOINTSA-N CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 PWTMJTJEUYXRGM-CHDDOINTSA-N 0.000 claims 1
• WOVNLPQSBXFSSV-MCGHGBNRSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)C3CC(O)(C3)C(F)(F)F)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)C3CC(O)(C3)C(F)(F)F)CC2)=N1 WOVNLPQSBXFSSV-MCGHGBNRSA-N 0.000 claims 1
• IDOMSJDEDQUAKX-BWVDUZJVSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 IDOMSJDEDQUAKX-BWVDUZJVSA-N 0.000 claims 1
• NJQSWCFXZVWOMT-OMHPJYQNSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 NJQSWCFXZVWOMT-OMHPJYQNSA-N 0.000 claims 1
• YWYFBRTZORKIBD-QQHARNDCSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 YWYFBRTZORKIBD-QQHARNDCSA-N 0.000 claims 1
• WOVNLPQSBXFSSV-NEBLVTBLSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)C3CC(O)(C3)C(F)(F)F)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)C3CC(O)(C3)C(F)(F)F)CC2)=N1 WOVNLPQSBXFSSV-NEBLVTBLSA-N 0.000 claims 1
• IDOMSJDEDQUAKX-LWPGTKICSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 IDOMSJDEDQUAKX-LWPGTKICSA-N 0.000 claims 1
• NJQSWCFXZVWOMT-NJSSPPMUSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 NJQSWCFXZVWOMT-NJSSPPMUSA-N 0.000 claims 1
• YWYFBRTZORKIBD-JENPDSIZSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 YWYFBRTZORKIBD-JENPDSIZSA-N 0.000 claims 1
• GIYCGBQBBYXNLG-QNNDVPKGSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 GIYCGBQBBYXNLG-QNNDVPKGSA-N 0.000 claims 1
• GIYCGBQBBYXNLG-DVAIQPOTSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 GIYCGBQBBYXNLG-DVAIQPOTSA-N 0.000 claims 1
• UDRZDLDHIYMICU-HUNBZTQFSA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-HUNBZTQFSA-N 0.000 claims 1
• UDRZDLDHIYMICU-WOKGGPCBSA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-WOKGGPCBSA-N 0.000 claims 1
• UDRZDLDHIYMICU-CPHHOOCTSA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-CPHHOOCTSA-N 0.000 claims 1
• JMUVTNVAYVZJCW-WHMPLDHSSA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 JMUVTNVAYVZJCW-WHMPLDHSSA-N 0.000 claims 1
• KAKCCJBQFXRMBC-JPAKECIRSA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 KAKCCJBQFXRMBC-JPAKECIRSA-N 0.000 claims 1
• JMUVTNVAYVZJCW-AKMOFFSESA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 JMUVTNVAYVZJCW-AKMOFFSESA-N 0.000 claims 1
• KAKCCJBQFXRMBC-CTOYOCAESA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 KAKCCJBQFXRMBC-CTOYOCAESA-N 0.000 claims 1
• GIAFISQEJLFPRO-LROMGURASA-N CC(C)c1cc(nc(n1)C(C)(C)C)N1CCN(CC[C@H]2CC[C@@H](CC2)NC(=O)[C@H]2CC[C@H](O)CC2)C[C@@H]1C Chemical compound CC(C)c1cc(nc(n1)C(C)(C)C)N1CCN(CC[C@H]2CC[C@@H](CC2)NC(=O)[C@H]2CC[C@H](O)CC2)C[C@@H]1C GIAFISQEJLFPRO-LROMGURASA-N 0.000 claims 1
• GYHDKJBMDCWPJZ-STUVXCIXSA-N FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 Chemical compound FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 GYHDKJBMDCWPJZ-STUVXCIXSA-N 0.000 claims 1
• GYHDKJBMDCWPJZ-CHDDOINTSA-N FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 Chemical compound FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 GYHDKJBMDCWPJZ-CHDDOINTSA-N 0.000 claims 1
• ZKQGJMPEAJQJIT-GHYQBBAPSA-N N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 ZKQGJMPEAJQJIT-GHYQBBAPSA-N 0.000 claims 1
• SQBFSJJWETYMEO-VGOHXSHPSA-N N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 SQBFSJJWETYMEO-VGOHXSHPSA-N 0.000 claims 1
• FOPADUAPJQWDQL-PWEACROJSA-N N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 FOPADUAPJQWDQL-PWEACROJSA-N 0.000 claims 1
• UNBJBRUJGOJLIT-VGOHXSHPSA-N N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 UNBJBRUJGOJLIT-VGOHXSHPSA-N 0.000 claims 1
• FRZXOHYLOHTWIQ-ZPSYDCNQSA-N N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 FRZXOHYLOHTWIQ-ZPSYDCNQSA-N 0.000 claims 1
• AFXBMUFMQUNQOQ-UKKGKWIZSA-N N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)C1CC(O)(C(F)(F)F)C1 Chemical compound N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)C1CC(O)(C(F)(F)F)C1 AFXBMUFMQUNQOQ-UKKGKWIZSA-N 0.000 claims 1
• SQBFSJJWETYMEO-MLRKGSHFSA-N N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 SQBFSJJWETYMEO-MLRKGSHFSA-N 0.000 claims 1
• FOPADUAPJQWDQL-WHLKPCPKSA-N N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 FOPADUAPJQWDQL-WHLKPCPKSA-N 0.000 claims 1
• UNBJBRUJGOJLIT-MLRKGSHFSA-N N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 UNBJBRUJGOJLIT-MLRKGSHFSA-N 0.000 claims 1
• FRZXOHYLOHTWIQ-XHPGVBHPSA-N N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 FRZXOHYLOHTWIQ-XHPGVBHPSA-N 0.000 claims 1
• MKGUUJLFVLEKNI-UNCSOSLYSA-N N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 Chemical compound N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 MKGUUJLFVLEKNI-UNCSOSLYSA-N 0.000 claims 1
• MKGUUJLFVLEKNI-YROJFRDXSA-N N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 Chemical compound N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 MKGUUJLFVLEKNI-YROJFRDXSA-N 0.000 claims 1
• FRZXOHYLOHTWIQ-UHFFFAOYSA-N n-[3-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclobutyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(C1)CC1NC(=O)C1CC(O)C1 FRZXOHYLOHTWIQ-UHFFFAOYSA-N 0.000 claims 1
• UNBJBRUJGOJLIT-UHFFFAOYSA-N n-[3-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclobutyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(C1)CC1NC(=O)C1CCC(O)CC1 UNBJBRUJGOJLIT-UHFFFAOYSA-N 0.000 claims 1
• GIYCGBQBBYXNLG-UHFFFAOYSA-N n-[3-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclobutyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CC(C3)NC(=O)C3CCC(O)CC3)CC2)=N1 GIYCGBQBBYXNLG-UHFFFAOYSA-N 0.000 claims 1
• UDRZDLDHIYMICU-AQNOAHGYSA-N n-[4-[2-[(3r)-4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]-3-methylpiperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-AQNOAHGYSA-N 0.000 claims 1
• UDRZDLDHIYMICU-IQAPFTQCSA-N n-[4-[2-[(3s)-4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]-3-methylpiperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-IQAPFTQCSA-N 0.000 claims 1
• XIPDODHKFSTWGQ-UHFFFAOYSA-N n-[4-[2-[4-(2,6-ditert-butylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 XIPDODHKFSTWGQ-UHFFFAOYSA-N 0.000 claims 1
• AFXBMUFMQUNQOQ-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(CC1)CCC1NC(=O)C1CC(O)(C(F)(F)F)C1 AFXBMUFMQUNQOQ-UHFFFAOYSA-N 0.000 claims 1
• SQBFSJJWETYMEO-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(CC1)CCC1NC(=O)C1CC(O)C1 SQBFSJJWETYMEO-UHFFFAOYSA-N 0.000 claims 1
• FOPADUAPJQWDQL-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-cyclopentylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCCC2)=CC=1N(CC1)CCN1CCC(CC1)CCC1NC(=O)C1CCC(O)CC1 FOPADUAPJQWDQL-UHFFFAOYSA-N 0.000 claims 1
• HFUDTZKQQFGRIB-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-propan-2-ylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 HFUDTZKQQFGRIB-UHFFFAOYSA-N 0.000 claims 1
• MKGUUJLFVLEKNI-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(1-methylcyclopropyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=CC=1C1(C)CC1 MKGUUJLFVLEKNI-UHFFFAOYSA-N 0.000 claims 1
• WOVNLPQSBXFSSV-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CC(O)(C3)C(F)(F)F)CC2)=N1 WOVNLPQSBXFSSV-UHFFFAOYSA-N 0.000 claims 1
• YWYFBRTZORKIBD-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CC(O)C3)CC2)=N1 YWYFBRTZORKIBD-UHFFFAOYSA-N 0.000 claims 1
• IDOMSJDEDQUAKX-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 IDOMSJDEDQUAKX-UHFFFAOYSA-N 0.000 claims 1
• NJQSWCFXZVWOMT-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-methoxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(CC3)OC)CC2)=N1 NJQSWCFXZVWOMT-UHFFFAOYSA-N 0.000 claims 1
• PWTMJTJEUYXRGM-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(difluoromethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 PWTMJTJEUYXRGM-UHFFFAOYSA-N 0.000 claims 1
• KAKCCJBQFXRMBC-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(methoxymethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CC(O)C3)CC2)=N1 KAKCCJBQFXRMBC-UHFFFAOYSA-N 0.000 claims 1
• JMUVTNVAYVZJCW-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(methoxymethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 JMUVTNVAYVZJCW-UHFFFAOYSA-N 0.000 claims 1
• GYHDKJBMDCWPJZ-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=C1 GYHDKJBMDCWPJZ-UHFFFAOYSA-N 0.000 claims 1
• 201000010099 disease Diseases 0.000 abstract description 26
• 230000001225 therapeutic effect Effects 0.000 abstract description 3
• 150000002431 hydrogen Chemical group 0.000 abstract 1
• 235000013350 formula milk Nutrition 0.000 description 178
• 239000000203 mixture Substances 0.000 description 34
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
• 125000001424 substituent group Chemical group 0.000 description 25
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
• 229940079593 drug Drugs 0.000 description 23
• 229910052757 nitrogen Inorganic materials 0.000 description 22
• 239000000243 solution Substances 0.000 description 21
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 20
• 125000004432 carbon atom Chemical group C* 0.000 description 19
• 102000005962 receptors Human genes 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
• 230000001276 controlling effect Effects 0.000 description 15
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
• 238000005160 1H NMR spectroscopy Methods 0.000 description 12
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
• 239000004480 active ingredient Substances 0.000 description 12
• 239000004615 ingredient Substances 0.000 description 12
• 208000020016 psychiatric disease Diseases 0.000 description 12
• 101150041968 CDC13 gene Proteins 0.000 description 11
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
• 238000003556 assay Methods 0.000 description 11
• 230000027455 binding Effects 0.000 description 11
• 238000009739 binding Methods 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 125000003545 alkoxy group Chemical group 0.000 description 10
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 108091006146 Channels Proteins 0.000 description 9
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 9
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 9
• 229910052799 carbon Inorganic materials 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
• 230000000926 neurological effect Effects 0.000 description 9
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
• 208000012902 Nervous system disease Diseases 0.000 description 8
• 208000025966 Neurological disease Diseases 0.000 description 8
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
• 125000001153 fluoro group Chemical group F* 0.000 description 8
• 239000003921 oil Substances 0.000 description 8
• 239000012044 organic layer Substances 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 229910052938 sodium sulfate Inorganic materials 0.000 description 8
• 235000011152 sodium sulphate Nutrition 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• 239000007832 Na2SO4 Substances 0.000 description 7
• RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• 208000028017 Psychotic disease Diseases 0.000 description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 206010012601 diabetes mellitus Diseases 0.000 description 6
• GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
• 230000003228 microsomal effect Effects 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 229960003638 dopamine Drugs 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 230000003907 kidney function Effects 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 201000009032 substance abuse Diseases 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 208000020401 Depressive disease Diseases 0.000 description 4
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 4
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 4
• 102000015554 Dopamine receptor Human genes 0.000 description 4
• 108050004812 Dopamine receptor Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 239000004698 Polyethylene Substances 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 230000003042 antagnostic effect Effects 0.000 description 4
• 239000000164 antipsychotic agent Substances 0.000 description 4
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
• 239000012267 brine Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000009109 curative therapy Methods 0.000 description 4
• IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 4
• 229960002994 dofetilide Drugs 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 239000012074 organic phase Substances 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 238000011321 prophylaxis Methods 0.000 description 4
• 235000018102 proteins Nutrition 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000006722 reduction reaction Methods 0.000 description 4
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
• 231100000736 substance abuse Toxicity 0.000 description 4
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 229940005529 antipsychotics Drugs 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 3
• BABWHSBPEIVBBZ-UHFFFAOYSA-N diazete Chemical compound C1=CN=N1 BABWHSBPEIVBBZ-UHFFFAOYSA-N 0.000 description 3
• 208000024732 dysthymic disease Diseases 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 239000007943 implant Substances 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 208000024714 major depressive disease Diseases 0.000 description 3
• 208000015238 neurotic disease Diseases 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 229940096717 pamine Drugs 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 241000894007 species Species 0.000 description 3
• OPGBSEXLSWYFOR-UHFFFAOYSA-N tert-butyl n-[4-(2-oxoethyl)cyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(CC=O)CC1 OPGBSEXLSWYFOR-UHFFFAOYSA-N 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000002110 toxicologic effect Effects 0.000 description 3
• 231100000027 toxicology Toxicity 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
• ZRFHLPAAPWZSOH-UHFFFAOYSA-N 2-tert-butyl-4-chloro-6-(2-methoxyethyl)pyrimidine Chemical compound COCCC1=CC(Cl)=NC(C(C)(C)C)=N1 ZRFHLPAAPWZSOH-UHFFFAOYSA-N 0.000 description 2
• DZYCPMJALSMMBK-UHFFFAOYSA-N 2-tert-butyl-6-cyclobutyl-1h-pyrimidin-4-one Chemical compound CC(C)(C)C1=NC(O)=CC(C2CCC2)=N1 DZYCPMJALSMMBK-UHFFFAOYSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• HRVPOSMAJRIZSP-UHFFFAOYSA-N 3-methoxycyclobutane-1-carboxamide Chemical compound COC1CC(C(N)=O)C1 HRVPOSMAJRIZSP-UHFFFAOYSA-N 0.000 description 2
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
• 208000008811 Agoraphobia Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
• 229910015845 BBr3 Inorganic materials 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 101150049660 DRD2 gene Proteins 0.000 description 2
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 206010022998 Irritability Diseases 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 108091006629 SLC13A2 Proteins 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 125000000909 amidinium group Chemical group 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 229940035678 anti-parkinson drug Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 208000028683 bipolar I disease Diseases 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 235000013877 carbamide Nutrition 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 206010007776 catatonia Diseases 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 238000010520 demethylation reaction Methods 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• OKKJLVBELUTLKV-MICDWDOJSA-N deuteriomethanol Chemical compound [2H]CO OKKJLVBELUTLKV-MICDWDOJSA-N 0.000 description 2
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 108010017146 dopamine D2L receptor Proteins 0.000 description 2
• 206010013663 drug dependence Diseases 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 210000001853 liver microsome Anatomy 0.000 description 2
• 238000011866 long-term treatment Methods 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• MREDTHNYKZZDIK-UHFFFAOYSA-N methyl 2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutylidene]acetate Chemical compound COC(=O)C=C1CC(NC(=O)OC(C)(C)C)C1 MREDTHNYKZZDIK-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 208000022821 personality disease Diseases 0.000 description 2
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 238000006268 reductive amination reaction Methods 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 235000019640 taste Nutrition 0.000 description 2
• VGPJTIFKZYJWDP-UHFFFAOYSA-N tert-butyl n-[3-(2-oxoethyl)cyclobutyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC(CC=O)C1 VGPJTIFKZYJWDP-UHFFFAOYSA-N 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 150000003672 ureas Chemical class 0.000 description 2
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
• UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
• ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
• VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
• STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
• MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
• YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
• AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
• 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
• 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
• 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
• 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
• JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
• DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
• 125000006345 2,2,2-trifluoroethoxymethyl group Chemical group [H]C([H])(*)OC([H])([H])C(F)(F)F 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
• FNHMJTUQUPQWJN-UHFFFAOYSA-N 2,2-dimethylpropanimidamide Chemical compound CC(C)(C)C(N)=N FNHMJTUQUPQWJN-UHFFFAOYSA-N 0.000 description 1
• FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• KIJRLDCFMIGNFA-UHFFFAOYSA-N 2-tert-butyl-4-(2-methoxyethyl)-1H-pyrimidin-6-one methyl 5-methoxy-3-oxopentanoate Chemical compound COC(CC(CCOC)=O)=O.C(C)(C)(C)C1=NC(=CC(=N1)O)CCOC KIJRLDCFMIGNFA-UHFFFAOYSA-N 0.000 description 1
• IHCPFUVJNRXPIZ-UHFFFAOYSA-N 2-tert-butyl-4-chloro-6-cyclobutylpyrimidine Chemical compound CC(C)(C)C1=NC(Cl)=CC(C2CCC2)=N1 IHCPFUVJNRXPIZ-UHFFFAOYSA-N 0.000 description 1
• QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
• JSMDUOFOPDSKIQ-UHFFFAOYSA-N 3-methoxypropanoyl chloride Chemical compound COCCC(Cl)=O JSMDUOFOPDSKIQ-UHFFFAOYSA-N 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• HCFRWBBJISAZNK-UHFFFAOYSA-N 4-Hydroxycyclohexylcarboxylic acid Chemical compound OC1CCC(C(O)=O)CC1 HCFRWBBJISAZNK-UHFFFAOYSA-N 0.000 description 1
• SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
• 102000035038 5-HT1 receptors Human genes 0.000 description 1
• 108091005478 5-HT1 receptors Proteins 0.000 description 1
• 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
• 108091005479 5-HT2 receptors Proteins 0.000 description 1
• 108060003345 Adrenergic Receptor Proteins 0.000 description 1
• 102000017910 Adrenergic receptor Human genes 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002859 Anxiety disorder due to a general medical condition Diseases 0.000 description 1
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
• 208000021465 Brief psychotic disease Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
• BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229940126657 Compound 17 Drugs 0.000 description 1
• 229940126639 Compound 33 Drugs 0.000 description 1
• 229940127007 Compound 39 Drugs 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000699662 Cricetomys gambianus Species 0.000 description 1
• 241000065675 Cyclops Species 0.000 description 1
• 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
• 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
• 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 208000024254 Delusional disease Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
• 101150097070 Drd3 gene Proteins 0.000 description 1
• JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000011688 Generalised anxiety disease Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
• 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 102000008015 Hemeproteins Human genes 0.000 description 1
• 108010089792 Hemeproteins Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000865224 Homo sapiens D(3) dopamine receptor Proteins 0.000 description 1
• 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 208000034592 Polysubstance dependence Diseases 0.000 description 1
• 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• 206010037213 Psychomotor retardation Diseases 0.000 description 1
• 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 1
• 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
• 208000036750 Schizophrenia, residual type Diseases 0.000 description 1
• 208000020186 Schizophreniform disease Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 208000019568 Shared Paranoid disease Diseases 0.000 description 1
• 208000028810 Shared psychotic disease Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
• 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 239000000150 Sympathomimetic Substances 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000018452 Torsade de pointes Diseases 0.000 description 1
• 208000002363 Torsades de Pointes Diseases 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 101100388144 Xenopus laevis drd5 gene Proteins 0.000 description 1
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
• SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
• PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
• CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
• FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 description 1
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
• WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 150000001263 acyl chlorides Chemical class 0.000 description 1
• 150000001266 acyl halides Chemical class 0.000 description 1
• 238000007792 addition Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000012826 adjustment disease Diseases 0.000 description 1
• 230000001800 adrenalinergic effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 230000002421 anti-septic effect Effects 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
• 229940064004 antiseptic throat preparations Drugs 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 230000000949 anxiolytic effect Effects 0.000 description 1
• 229940005530 anxiolytics Drugs 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
• 229960004754 astemizole Drugs 0.000 description 1
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
• 208000025748 atypical depressive disease Diseases 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
• 239000012148 binding buffer Substances 0.000 description 1
• 208000022257 bipolar II disease Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 210000003793 centrosome Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
• 229960001380 cimetidine Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 229940126543 compound 14 Drugs 0.000 description 1
• 229940125758 compound 15 Drugs 0.000 description 1
• 229940126142 compound 16 Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 229940126086 compound 21 Drugs 0.000 description 1
• 229940126208 compound 22 Drugs 0.000 description 1
• 229940125833 compound 23 Drugs 0.000 description 1
• 229940125961 compound 24 Drugs 0.000 description 1
• 229940125846 compound 25 Drugs 0.000 description 1
• 229940125851 compound 27 Drugs 0.000 description 1
• 229940127204 compound 29 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125877 compound 31 Drugs 0.000 description 1
• 229940125878 compound 36 Drugs 0.000 description 1
• 229940125807 compound 37 Drugs 0.000 description 1
• 229940127573 compound 38 Drugs 0.000 description 1
• 229940126540 compound 41 Drugs 0.000 description 1
• 229940125936 compound 42 Drugs 0.000 description 1
• 229940125844 compound 46 Drugs 0.000 description 1
• 229940127271 compound 49 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 150000004292 cyclic ethers Chemical class 0.000 description 1
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
• 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
• 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
• 208000026725 cyclothymic disease Diseases 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 229940113088 dimethylacetamide Drugs 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 125000006419 fluorocyclopropyl group Chemical group 0.000 description 1
• 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000029364 generalized anxiety disease Diseases 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 235000015201 grapefruit juice Nutrition 0.000 description 1
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 239000000380 hallucinogen Substances 0.000 description 1
• 150000008282 halocarbons Chemical class 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 230000002140 halogenating effect Effects 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 239000000416 hydrocolloid Substances 0.000 description 1
• 206010020765 hypersomnia Diseases 0.000 description 1
• 239000003326 hypnotic agent Substances 0.000 description 1
• 230000000147 hypnotic effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
• 206010021654 increased appetite Diseases 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000003715 limbic system Anatomy 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 239000002075 main ingredient Substances 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 240000004308 marijuana Species 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000012907 medicinal substance Substances 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 201000003995 melancholia Diseases 0.000 description 1
• GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
• OPURNNHYTATPKM-UHFFFAOYSA-N methyl 5-methoxy-3-oxopentanoate Chemical compound COCCC(=O)CC(=O)OC OPURNNHYTATPKM-UHFFFAOYSA-N 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 208000025319 neurotic depression Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• 210000001009 nucleus accumben Anatomy 0.000 description 1
• PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
• 239000003605 opacifier Substances 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 150000004967 organic peroxy acids Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 208000002851 paranoid schizophrenia Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229950010883 phencyclidine Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
• UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
• IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
• FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229940068917 polyethylene glycols Drugs 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 208000028173 post-traumatic stress disease Diseases 0.000 description 1
• 239000008057 potassium phosphate buffer Substances 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 238000009117 preventive therapy Methods 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 229940070376 protein Drugs 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 208000022610 schizoaffective disease Diseases 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 208000012672 seasonal affective disease Diseases 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 230000000862 serotonergic effect Effects 0.000 description 1
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
• 230000002295 serotoninergic effect Effects 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
• 229950001675 spiperone Drugs 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 201000006152 substance dependence Diseases 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000001975 sympathomimetic effect Effects 0.000 description 1
• 229940064707 sympathomimetics Drugs 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 230000002618 waking effect Effects 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000002676 xenobiotic agent Substances 0.000 description 1